March 21, 2025

Pushing the limits of ‘custom-made’ microscopy

Pushing the limits of ‘custom-made’ microscopy

Another EMBL-engineered advance to Brillouin microscopy significantly widens the aperture and provides for quick, more efficient 3-D imaging of light-sensitive samples

An artist’s representation of the new Brillouin microscopy approach that allows entire light-sheets to interact with 3D biological samples. The scattered light reveals a unique optical interference signal that can be recorded with a custom-developed spectrometer, tremendously speeding up image acquisition. Credit: Daniela Velasco/EMBL

Summary

  • PreviouslyEMBL scientists developed a new microscope based on Brillouin scattering – a phenomenon where light interacts with naturally occurring thermal vibrations within materials, from which their mechanical properties can be deduced. This method has since been used for non-invasive and live-imaging applications in biology, and that advance was selected as one of The Guardian’s 10 biggest science stories of 2022.
  • In a new paper, the same scientists have now succeeded in substantially further advancing Brillouin microscopy, making it approximately a thousand times faster and more efficient.
  • Simultaneously, the new microscopy method expands the swath of material it can view – from a 100-pixel line to a ~10,000-pixel full plane, capturing 3D images quickly enough for live-organism observation.

A new paper updates an EMBL technology advance even further. More details about the original technology can be found in our initial reporting here.

EMBL tech developers have made an important leap forward with a novel methodology that adds an important microscopy capability to life scientists’ toolbox. The advance represents a 1,000-fold improvement in speed and throughput in Brillouin microscopy and provides a way to view light-sensitive organisms more efficiently.

“We were on a quest to speed up image acquisition,” said Carlo Bevilacqua, lead author on a paper published about this technological development in Nature Photonics and an optical engineer in EMBL’s Prevedel Team. “Over the years, we have progressed from being able to see just a pixel at a time to a line of 100 pixels, to now a full plane that offers a view of approximately 10,000 pixels.”

The technology is based on a phenomenon first predicted in 1922 by French physicist Léon Brillouin. He showed that when light is shone on a material, it interacts with naturally occurring thermal vibrations within, exchanging energy and thereby slightly shifting the frequency (or colour) of the light. Measuring the spectrum (colours) of the scattered light reveals information about a material’s physical characteristics.

Using Brillouin scattering for microscopy purposes came much later – in the early 2000s – when other technological advancements enabled scientists to measure tiny frequency shifts with high precision and sufficient throughput. This allowed them to compute mechanical properties of living biological samples. However, at that point, scientists were only able to view one pixel at a time. The process was therefore quite time-consuming, and it severely limited how the microscopy method could be used in biology. In 2022, Bevilacqua and others in the Prevedel group were able to first expand the field of view to a line, and now with this latest development, to a full 2D field of view, which also helps speed up 3D imaging.

“Just as the development of light-sheet microscopy here at EMBL marked a revolution in light microscopy because it allowed for faster, high-resolution, and minimally phototoxic imaging of biological samples, so too does this advance in the area of mechanical or Brillouin imaging,” said Robert Prevedel, Group Leader and senior author on the paper. “We hope this new technology – with minimal light intensity – opens one more ‘window’ for life scientists’ exploration.”


Source article(s)

Full-field Brillouin microscopy based on an imaging Fourier transform spectrometer. Bevilacqua C. and Prevedel R. Nature Photonics 20 February 2025 10.1038/s41566-025-01619-y

Our latest News

discover more
Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Effective June 1, 2026, the Supervisory Board has appointed Hanns-Peter Knaebel, Chairman of the Executive Board, to serve as Chief Medical Officer. This move will ensure that the dynamic phase of medical strategy development and transformation within the group is overseen and managed centrally by the full Executive Board. Full Text in German below. Professor […]

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

HEILBRONN, Germany, May 14, 2026 – ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing. ProtaGene’s expertise in advanced protein […]

Universität Heidelberg Successful with Application for Collaborative Research Centre

Universität Heidelberg Successful with Application for Collaborative Research Centre

DFG funds extended CRC with approximately 17.4 million euros Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp